Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases.

Kim WY, Woo SU, Seo JH, Son GS, Lee JB, Bae JW.

J Cancer Res Ther. 2011 Oct-Dec;7(4):412-5. doi: 10.4103/0973-1482.92004.

PMID:
22269401
[PubMed - indexed for MEDLINE]
Free Article
2.
3.

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.

Clin Breast Cancer. 2002 Oct;3(4):268-75.

PMID:
12425755
[PubMed - indexed for MEDLINE]
4.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N.

J Clin Oncol. 2013 Sep 10;31(26):3197-204. doi: 10.1200/JCO.2012.48.1275. Epub 2013 Aug 12.

PMID:
23940225
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR.

Ann Oncol. 2006 Aug;17(8):1205-12. Epub 2006 Jun 9.

PMID:
16766587
[PubMed - indexed for MEDLINE]
Free Article
6.

[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].

Wu WH, Li Q, Xu BH, Zhang P, Zhao LM, Yuan P, Wang JY, Cai RG, Zhou AP.

Zhonghua Zhong Liu Za Zhi. 2008 Jul;30(7):548-51. Chinese.

PMID:
19062727
[PubMed - indexed for MEDLINE]
7.

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.

Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J.

Breast Cancer Res Treat. 2013 Jun;139(3):863-72. doi: 10.1007/s10549-013-2582-2. Epub 2013 Jun 16.

PMID:
23771731
[PubMed - indexed for MEDLINE]
8.

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.

Rom J, von Minckwitz G, Eiermann W, Sievert M, Schlehe B, Marmé F, Schuetz F, Scharf A, Eichbaum M, Sinn HP, Kaufmann M, Sohn C, Schneeweiss A.

Ann Oncol. 2008 Oct;19(10):1698-705. doi: 10.1093/annonc/mdn280. Epub 2008 May 13.

PMID:
18477581
[PubMed - indexed for MEDLINE]
Free Article
9.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Caratení G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.

PMID:
9694607
[PubMed - indexed for MEDLINE]
10.

Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.

Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.

Oncology. 2006;70(4):290-3. Epub 2006 Aug 4.

PMID:
16899982
[PubMed - indexed for MEDLINE]
11.

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.

Mitchell PL, Basser R, Chipman M, Grigg A, Mansfield R, Cebon J, Davis ID, Appia F, Green M.

Ann Oncol. 2004 Apr;15(4):585-9.

PMID:
15033663
[PubMed - indexed for MEDLINE]
Free Article
12.

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.

Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, Ahn SH.

Cancer Chemother Pharmacol. 2012 May;69(5):1221-7. doi: 10.1007/s00280-011-1816-4. Epub 2012 Jan 20.

PMID:
22271208
[PubMed - indexed for MEDLINE]
13.

Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.

Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F.

Ann Oncol. 1997 Jul;8(7):655-61.

PMID:
9296218
[PubMed - indexed for MEDLINE]
Free Article
14.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM; Hellenic Cooperative Oncology Group.

Ann Oncol. 2008 May;19(5):853-60. Epub 2007 Nov 27.

PMID:
18042835
[PubMed - indexed for MEDLINE]
Free Article
15.

Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.

Cousin S, Le Rhun E, Mailliez A, Fournier C, Bonneterre J.

Bull Cancer. 2012 Jul-Aug;99(7-8):75-80. doi: 10.1684/bdc.2012.1607.

PMID:
22713627
[PubMed - indexed for MEDLINE]
16.

Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.

Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R.

Support Care Cancer. 2011 Apr;19(4):497-504. doi: 10.1007/s00520-010-0843-8. Epub 2010 Mar 17.

PMID:
20232087
[PubMed - indexed for MEDLINE]
17.

Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.

Clin Breast Cancer. 2002 Dec;3(5):333-40.

PMID:
12533263
[PubMed - indexed for MEDLINE]
18.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
[PubMed - indexed for MEDLINE]
19.

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.

Wolowacz SE, Cameron DA, Tate HC, Bagust A.

J Clin Oncol. 2008 Feb 20;26(6):925-33. doi: 10.1200/JCO.2006.10.4190.

PMID:
18281666
[PubMed - indexed for MEDLINE]
Free Article
20.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B.

Cancer Treat Rev. 2008 May;34(3):223-30. doi: 10.1016/j.ctrv.2007.11.004. Epub 2008 Jan 30.

PMID:
18234424
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk